Ganaxolone Treatment in Children With Fragile X Syndrome
A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
Sponsor: Marinus Pharmaceuticals
Listed as NCT01725152, this PHASE2 trial focuses on Fragile x Syndrome and remains completed. Sponsored by Marinus Pharmaceuticals, it has been updated 12 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — May 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2019 — Sep 2020 [monthly]
Completed PHASE2
-
Jul 2018 — Aug 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Marinus Pharmaceuticals
- U.S. Army Medical Research and Development Command
- University of California, Davis
For direct contact, visit the study record on ClinicalTrials.gov .